Unbound MEDLINE

Hepatic arterial infusion for unresectable colorectal liver metastases combined or not with systemic chemotherapy. Anticancer research [Anticancer Res] Journal article

 
TitleHepatic arterial infusion for unresectable colorectal liver metastases combined or not with systemic chemotherapy.
Author(s)Pilati P, Mammano E, Mocellin S, Tessari E, Lise M, Nitti D 
InstitutionDepartment of Oncological and Surgical Sciences, Surgery Branch, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy. enzo.mammano@unipd.it.
SourceAnticancer Res 2009 Oct; 29(10):4139-44.
AbstractBACKGROUND: The hypothesis was tested that systemic chemotherapy might contribute to improving overall survival (OS) of patients with unresectable colorectal liver metastases treated with hepatic arterial infusion (HAI).
PATIENTS AND METHODS: We considered 153 consecutive patients retrospectively divided into group A (n=72) treated with HAI alone (floxuridine [FUDR] + leucovorin [LV]), and group B (n=81) treated with HAI combined with systemic chemotherapy (5-fluorouracil [5FU] + LV).
RESULTS: No significant difference in OS was observed between the two groups. Median OS was better in patients with <50% of liver involvement (21.3 vs. 13.2 months; p<0.0001) and in responders vs. non-responders (24.4 vs. 13.4 months; p<0.0001). The combination of low tumor load with good tumor response to HAI was the only variable retained on multivariate survival analysis, associated with a better clinical outcome (median OS: 34.2 months).
CONCLUSION: Our study does not support the use of FUDR-based HAI combined or not with 5FU-based systemic chemotherapy as the first-line therapeutic approach to unresectable colorectal cancer liver metastases. The identification of responsive patients would improve the therapeutic index of this HAI regimen.
Languageeng
Pub Type(s)Journal Article
PubMed ID19846962
  
Advertise on this site.